Gillian Parker

Nov 21, 2024 | mdpi.com | Gillian Parker |Fiona A. Miller

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Apr 23, 2024 | medrxiv.org | Gillian Parker |Sarah Hunter |Karen Born

The authors have declared no competing interest. YesI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Approval: Not applicable.

Dec 11, 2023 | impact.economist.com | Gillian Parker

Gillian Parker sustainability lead for APAC at Economist Impactmore_horizPUBLISHED 11 DECEMBER, 2023 • 5 MIN READIn a world hurtling towards a future where over two-thirds of the global population will reside in cities by 2050, urban areas stand as humanity’s frontline against the unpredictable challenges of the 21st century.

Apr 27, 2023 | journals.plos.org | Gillian Parker |Sarah Hunter |Fiona A. Miller |Stuart Hogarth

Loading metrics Open Access Peer-reviewedResearch Article AbstractBackgroundDecision impact studies have become increasingly prevalent in genomic medicine, particularly in cancer research. Such studies are designed to provide evidence of clinical utility for genomic tests by evaluating their impact on clinical decision-making.